logo
episode-header-image
Sep 2023
35m 38s

Why One Drug Company Held Back a Better ...

The New York Times
About this episode
For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents. Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and h ... Show More
Up next
Today
How Trump Was Persuaded to Regulate A.I.
President Trump has begrudgingly accepted that artificial intelligence requires oversight and on Tuesday signed an executive order asking companies to voluntarily give the government access to new models before they’re released to the public. Tripp Mickle, who covers Silicon Vall ... Show More
34m 13s
Yesterday
Why the Ebola Outbreak Has Been Nearly Impossible to Stop
At the front lines of the Ebola crisis in Central Africa, badly equipped health workers with little outside support are losing the fight against one of the worst outbreaks in history. Declan Walsh, a New York Times correspondent covering the outbreak, takes us to the epicenter of ... Show More
30m 32s
Jun 2
How Elon Musk Engineered the World’s Biggest I.P.O.
SpaceX, Elon Musk’s rocket and satellite maker, is set to go public and begin selling shares as soon as next week. Ryan Mac, who reports on business, explains the plan for the company’s expected record-shattering debut on the stock market, and how it is changing the rules for inv ... Show More
30m 37s
Recommended Episodes
Jul 2022
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ... Show More
15m 33s
Oct 2021
Sick Money (Pt 1): Exposing the drug companies' price gouging tactics
<p>In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. </p><p>How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 1 ... Show More
29m 31s
Mar 2024
Long Reads: Big Pharma's Toxic Record w/ Nick Dearden
<p>From the HIV/AIDS crisis, to the opioid epidemic, to the COVID-19 pandemic, pharmaceutical corporations have been accused of profiteering at the expense of countless lives. Nick Dearden, director of Global Justice Now and the author of a new book called <a href="https://www.ve ... Show More
53m 19s
Jan 2020
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ... Show More
12m 36s
Apr 2021
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ... Show More
12m 48s
Jul 2023
Sawbones: Patents vs. Life-Saving Drugs
<p>John Green recently made a video asking Johnson & Johnson not to extend their patent on a tuberculosis drug, which would keep it exclusive and expensive. Dr. Sydnee and Justin talk about how drug patents work, the recent (good) update about bedaquiline specifically, and the ne ... Show More
38m 46s
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s
Jun 2016
GW's Gover on Cannabis-Derived Drug for Rare Epilepsy (Audio)
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades. Learn more about your ad-choices at https://www ... Show More
8m 27s
Mar 2024
Eli Lilly CEO Dave Ricks Talks Fighting Obesity, Developing New Drugs
Eli Lilly CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club of New York, the head of the pharma giant says that they are looking to create an oral tablet i ... Show More
7m 50s